Retinal Vein Occlusion Pipeline Insight, 2026

DelveInsight’s, “Retinal Vein Occlusion Pipeline Insight 2026” report provides comprehensive insights about 13+ companies and 14+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Retinal Vein Occlusion Disease Understanding

Retinal Vein Occlusion Overview

Retinal Vein Occlusion (RVO) is a vascular eye disorder in which the veins responsible for draining blood from the retina become obstructed, most commonly due to thrombus formation. This blockage disrupts normal blood flow, resulting in retinal ischemia, fluid accumulation, and visual impairment. It is recognized as the second most prevalent retinal vascular disease and a significant cause of vision loss, particularly among the elderly. The condition is frequently associated with systemic risk factors such as hypertension, diabetes, and atherosclerosis.

Clinically, RVO typically presents with sudden, painless vision blurring or loss in one eye, which may be partial or severe depending on the extent of involvement. Patients may also experience distorted or dim vision due to macular edema, along with floaters or visual field defects. In some cases, especially ischemic central RVO, vision loss can be abrupt and profound, while others may show gradual deterioration if untreated. The disease is categorized into central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), and hemi-central retinal vein occlusion (hemi-CRVO), based on the location and extent of venous blockage. 

Diagnosis of Retinal Vein Occlusion (RVO) involves a thorough ophthalmic evaluation, including assessment of visual acuity and intraocular pressure. Fundoscopic examination often shows characteristic findings such as retinal hemorrhages, dilated and tortuous veins, and macular edema. Advanced imaging techniques like Optical Coherence Tomography (OCT) are used to evaluate retinal thickness and detect fluid accumulation, while fluorescein angiography helps assess retinal blood flow and identify areas of leakage or occlusion. Additional blood tests may be performed to identify underlying systemic conditions such as diabetes, lipid abnormalities, or coagulation disorders, and early diagnosis is essential for prompt management and vision preservation.

Treatment of Retinal Vein Occlusion (RVO) primarily aims to control complications such as macular edema and to preserve visual function. Intravitreal administration of anti-VEGF agents are widely used to reduce retinal swelling and improve vision outcomes. In patients who respond inadequately, corticosteroid injections or implants may be considered as alternative options. Laser photocoagulation therapy can help manage retinal ischemia and limit abnormal blood vessel growth, while effective control of underlying conditions such as hypertension, diabetes, and glaucoma is essential to lower recurrence risk.

"Retinal Vein Occlusion Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Retinal Vein Occlusion pipeline landscape is provided, including the disease overview and Retinal Vein Occlusion treatment guidelines. The assessment part of the report embraces, in depth Retinal Vein Occlusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinal Vein Occlusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Retinal Vein Occlusion Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Retinal Vein Occlusion R&D. The therapies under development are focused on novel approaches to treat/improve Retinal Vein Occlusion.

Retinal Vein Occlusion Emerging Drugs Analysis

This segment of the Retinal Vein Occlusion report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Retinal Vein Occlusion Emerging Drugs

Tarcocimab tedromer: Kodiak sciences

Tarcocimab tedromer is an investigational anti-VEGF therapy developed using Kodiak’s Antibody Biopolymer Conjugate (ABC) platform, engineered to sustain therapeutic drug concentrations in ocular tissues for longer durations compared to currently available treatments. Its clinical development program is structured to evaluate durability, efficacy, and safety across multiple retinal disorders, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and non-proliferative diabetic retinopathy (NPDR) without DME, through parallel studies. Key trials such as GLEAM and GLIMMER (DME), BEACON (RVO), DAYLIGHT (wet AMD), and GLOW (NPDR) are expected to support a Biologics License Application (BLA) for potential approval across multiple indications. At present, tarcocimab tedromer is in Phase III clinical development for the treatment of retinal vein occlusion. 

MK-8748: Merck

MK-8748 is a bispecific antibody engineered as a bi-functional Fc-fusion protein that simultaneously targets angiogenic and vascular stability pathways. It acts as a TIE2 receptor agonist to promote vascular stabilization while also functioning as a VEGF antagonist, thereby reducing pathological angiogenesis and vascular leakage associated with retinal vein occlusion. This dual mechanism is designed to improve retinal vascular integrity and control edema more effectively than single-pathway therapies. The molecule was obtained through the acquisition of Eyebiotech Limited (EyeBio), strengthening its development pipeline in ophthalmology. MK-8748 is currently being investigated for the treatment of retinal vein occlusion and is in Phase II stage of its development.
Further product details are provided in the report……..

Retinal Vein Occlusion Drug Therapeutic Assessment

This segment of the report provides insights about the different Retinal Vein Occlusion drugs segregated based on following parameters that define the scope of the report, such as:

Major Retinal Vein Occlusion Players in Retinal Vein Occlusion  

• There are approx. 13+ key companies which are developing the therapies for Retinal Vein Occlusion. The companies which have their Retinal Vein Occlusion drug candidates in the most advanced stage, i.e. Phase III include, Kodiak Sciences.

Retinal Vein Occlusion Clinical Trial Phases

DelveInsight’s report covers around 14+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Retinal Vein Occlusion Drug Route of Administration

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Retinal Vein Occlusion Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Retinal Vein Occlusion Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Retinal Vein Occlusion Clinical Trial Activities

The Retinal Vein Occlusion Pipeline report provides insights into Retinal Vein Occlusion Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Retinal Vein Occlusion therapeutic drugs key players involved in developing key drugs. 

Retinal Vein Occlusion Pipeline Development Activities

The Retinal Vein Occlusion Clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinal Vein Occlusion drugs.

Retinal Vein Occlusion Pipeline Report Insights

• Retinal Vein Occlusion Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Retinal Vein Occlusion Pipeline Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered In The Retinal Vein Occlusion Pipeline Report

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Retinal Vein Occlusion drugs?
• How many Retinal Vein Occlusion drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Retinal Vein Occlusion?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Retinal Vein Occlusion therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Retinal Vein Occlusion and their status?
• What are the key designations that have been granted to the emerging drugs?

Retinal Vein Occlusion Key Companies

• Kodiak sciences
• Merck
• Annexin Pharmaceutical
• Kalaris Therapeutics
• Perfuse Therapeutics
• PulseSight Therapeutics

Retinal Vein Occlusion Key Products

• Tarcocimab tedromer
• MK-8748
• ANXV
• TH103
• PER-001
• PST 809"